Fundraising Fox
/Companies
Sign in

Hephaistos-Pharma

Orsay, FR · Founded 2018 · 19 employees on LinkedIn · 6 known investors

Find your way into Hephaistos-Pharma

548 people in our graph can introduce you to the Hephaistos-Pharma team.

Sign up to see every warm intro you have to Hephaistos-Pharma

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Hephaistos-Pharma team. We find them
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

HEPHAISTOS is a biopharmaceutical company developing third-generation innate immune boosters (TLR4 agonists) that convert myeloid-rich, immunotherapy-resistant tumors into immunotherapy-responsive tumors. Its lead candidate HEPHA440 targets front-line cancer therapy and is scheduled to enter clinical trials in 2027.

BiotechMedical Devices

Founders & leadership

Hephaistos-Pharma was founded in 2018 by Martine Caroff.

MCMartine Caroff
Martine CaroffScientific FounderMartine Caroff is founder and Chief Scientific Officer of Hephaistos-Pharma, a biopharmaceutical company developing immune-stimulating therapeutics for oncology. She previously held the position of Research Director at the French National Center for Scientific Research (CNRS) and has specialized expertise in lipopolysaccharide structure and function.
FCFrederic Caroff
Frederic CaroffCEO
FBFrederique Brune
Frederique BruneCDO
SBStephan Braun
Stephan BraunCMOStephan Braun is CMO of Hephaistos-Pharma and has held roles across oncology drug development, clinical-regulatory strategy, and biomarker development. He is board-certified in obstetrics and gynecology with qualifications in gyneco-oncology, and has founded a medtech company and holds medtech patents.
JKJerome Kerzerho
Jerome KerzerhoCSOJerome Kerzerho is an immunologist with 15+ years of experience in pharmaceutical and biotech R&D, with expertise in preclinical development of cancer immunotherapies and vaccines. As Chief Scientific Officer at Hephaistos-Pharma, he oversees immuno-oncology, pharmacology, and toxicology programs for the company's TLR4 agonist pipeline.
CLChristel Lonneux
Christel LonneuxCFO and HR

Board

DSDavid Sourdive
David SourdiveChairman of the BoardVenture Partner at Elaia

Investors · 6

Elaia✓ confirmed by Hephaistos-PharmaParis · $108K – $1.6M

How we know: the company's own site · frenchtechjournal.com · Not right? Tell us

Angels Santélisted by Angels SantéParis

How we know: Angels Santé's portfolio page · frenchtechjournal.com · open dataset · 5k.vc investor directory · Not right? Tell us

Femmes Business Angelslisted by Femmes Business AngelsParis · $55K – $220K

How we know: Femmes Business Angels's portfolio page · frenchtechjournal.com · Not right? Tell us

Also in the syndicate · 2

Fondation Fournier-MajoieNoshaq

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Hephaistos-Pharma Raises €10.3M in Fundingfinsmes.com · May 2024

Frequently asked questions

What does Hephaistos-Pharma do?
HEPHAISTOS is a biopharmaceutical company developing third-generation innate immune boosters (TLR4 agonists) that convert myeloid-rich, immunotherapy-resistant tumors into immunotherapy-responsive tumors. Its lead candidate HEPHA440 targets front-line cancer therapy and is scheduled to enter clinical trials in 2027.
Who founded Hephaistos-Pharma?
Hephaistos-Pharma was founded by Martine Caroff in 2018.
Who are Hephaistos-Pharma's investors?
Hephaistos-Pharma's investors include xista science ventures, Elaia, Angels Santé, Femmes Business Angels.
Where is Hephaistos-Pharma headquartered?
Hephaistos-Pharma is headquartered in Orsay, FR.